Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

ResMed (RMD) Q3 Earnings: Disappointment In The Cards?

By Zacks Investment ResearchStock MarketsApr 17, 2017 09:27PM ET
www.investing.com/analysis/resmed-(rmd)-q3-earnings:-disappointment-in-the-cards-200183440
ResMed (RMD) Q3 Earnings: Disappointment In The Cards?
By Zacks Investment Research   |  Apr 17, 2017 09:27PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

ResMed Inc. (NYSE:RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.

Last quarter, the company posted a positive earnings surprise of 4.29%. The four-quarter average earnings beat is 0.31%. Let's see how things are shaping up for this announcement.

Factors at Play

In the previously reported second quarter, ResMed’s masks segment saw 7% year-over-year decline in sales. The company has been particularly concerned about sluggish mask growth in the EMEA and APAC regions for quite some time now. Even though the AirFit F20 and AirFit N20 masks have been introduced in these regions, management expects the underperformance to continue in the third quarter of 2017 as well.

ResMed Inc. Price and EPS Surprise

ResMed Inc. Price and EPS Surprise | ResMed Inc. Quote

Meanwhile, the company generates a significant portion of its revenues from international sales. Therefore, currency headwinds continue to affect ResMed’s overseas sales.

Moreover, overall macroeconomic uncertainty is a major obstacle for growth. Thus, the company is cautiously handling its international operations.

Another factor which has been acting as a dampener for margins is its rising operating expenses. Management projects a further escalation in costs associated with product launches and legal expenses in the second half of 2017.

Also, the market for sleep-disordered breathing (SDB) products is highly competitive with respect to product price, features and reliability. Other challenges like competitive bidding and reimbursement pressure continue to hurt the stock.

On the bright side, ResMed continues to enjoy high demand for its SDB products. Recently, the company unveiled positive data related to its adaptive servo-ventilation (ASV) therapy’s ability to treat patients with sleep apnea. The company’s current endeavors to gain traction in the SDB market are expected to boost revenues.

ResMed is currently planning to expand its base in international markets. The company has seen growth in China buoyed by strong execution of integration plans and better team work. ResMed expects to maintain this bullish trend in the forthcoming quarters as well. Management is also currently focusing on consolidating its presence in Europe with respect to its life support ventilation and non-invasive ventilation solutions.

Earnings Whispers

Our proven model does not conclusively show that ResMed is likely to beat earnings this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. That is not the case here, as you will see below.

Zacks ESP: ResMed has an Earnings ESP of 0.00%. That is because both the Most Accurate estimate and the Zacks Consensus Estimate are pegged at 70 cents. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

Zacks Rank: ResMed has a Zacks Rank #4 (Sell). Please note that we caution against stocks with a Zacks Rank #4 or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Stocks to Consider

Here are some companies you may consider as our model shows that they have the right combination of elements to post an earnings beat in the upcoming quarter:

Galectin Therapautics, Inc. (NASDAQ:GALT) has an Earnings ESP of +13.33% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.

Hill-Rom Holdings Inc (NYSE:HRC) has an Earnings ESP of +1.27% and a Zacks Rank #2.

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) has an Earnings ESP of +3.85% and a Zacks Rank #2.

5 Trades Could Profit "Big-League" from Trump Policies

If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.

Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure. See these buy recommendations now >>



ResMed Inc. (RMD): Free Stock Analysis Report

Hill-Rom Holdings Inc (HRC): Free Stock Analysis Report

Syros Pharmaceuticals, Inc. (SYRS): Free Stock Analysis Report

Galectin Therapeutics Inc. (GALT): Free Stock Analysis Report

Original post

Zacks Investment Research
ResMed (RMD) Q3 Earnings: Disappointment In The Cards?
 

Related Articles

Declan Fallon
Indices Attempt Support Rally By Declan Fallon - Sep 17, 2021 2

Markets aren't exactly powering higher but there is an attempt to develop some form of swing low. The NASDAQ has the clearest opportunity. The last couple of 'white' candlesticks...

ResMed (RMD) Q3 Earnings: Disappointment In The Cards?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email